CTRI/2009/091/000546招募中2 期
Safety and efficacy of HO/03/03 in the treatment of Planatar Neuropathic Diabetic Foot Ulcers.
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- HealOr Ltd.
- 入组人数
- 146
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age between 18 and 80 years, extremes included;
- •2. Diagnosed with Diabetes Mellitus Type 1 or Type 2;
- •3. Having a documented single non-healing Plantar Neuropathic Diabetic Foot Ulcer (per subject) with a minimal duration of 4 weeks prior to the informed consent signature;
- •4. Ulcer size at randomization between 1.0 cm2 to 10 cm2, extremes included;
- •5. Single, full thickness ulcer on the study foot, depth is no more than exposed muscle ? Wagner grade 1 (does not involve exposed tendon,ligament, joint capsule, fascia or bone, no abscess or osteomyelitis);
- •6. Glycosylated Haemoglobin A1c (HbA1c) <= 12%;
- •7. Ankle to Brachial Index (ABI) on study foot:
- •1. 0.7 <= ABI <= 1.2 or
- •2. ABI > 1.2 and toe pressure > 50 mm Hg
- •(ABI measured by Doppler; toe blood pressure measured in a vascular lab);
- •8. Diabetic Neuropathy is confirmed by neurological testing
- •9. Subject should be available for the entire study period, and be able and willing to adhere to protocol requirements;
- •10.Subject has signed the informed consent form prior to any study protocol related procedure;
排除标准
- •1. Anamnesis of current or recent past (within the last 2 years) abuse of alcohol, barbiturates, benzodiazepines, amphetamines, narcotics, cocaine,psychoactive drugs or other abused substances (licit or illicit) that will
- •interfere with treatment compliance;
- •2. Use of growth factors, skin graft or participation in an investigational study within the last 30 days prior to the beginning of the screening period;
- •3. Females who are pregnant, lactating, of child-bearing potential, or postmenopausal for less than 2 years and not using a medically approved method of contraception (i.e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterility), or females who test positive on a blood-based pregnancy test.
- •4. Have a documented medical history of HIV, HBV or HCV;
- •5. Have a documented medical history of a significant cardiac, pulmonary, gastrointestinal, endocrine (other than Diabetes Mellitus type 1 or 2), metabolic, neurological, hepatic or nephrologic disease and/or receiving dialysis;
- •6. Anaemia (Haemoglobin < 9 gram/dL for females or Haemoglobin < 10 gram/dL for males) or White Blood Cells count > 11,000/μL or Platelets count < 100,000/μL or impaired renal function (Creatinine > 3 mg/dL) or
- •liver function tests > 3 times normal lab values or any indication of malnourishment (Albumin < 2.8 g/dL) or any other clinically significant biochemistry, haematology and urinalysis tests;
- •7. Had any clinically significant illness during the last 4 weeks prior to the screening period;
- •8. Have a current malignancy or a past malignancy in the last 5 years other than Basal Cell Carcinoma or is treated by radio/chemotherapy;
- •9. Ulcer involves or exposes tendon, ligament, joint, fascia or bone at wound site;
- •10.Have any signs of clinical infection in the wound (which could be linked to raised body temperature), abscess, osteomyelitis, necrosis or erythema);
- •11.Had any antibiotic treatment during the screening period;
- •12.Had evidence of infection or osteomyelitis on a plain foot x-ray at screening;
- •13.Is bed-ridden or unable to come to the clinic;
- •14.Have more than one non-healing Diabetic Foot Ulcer per subject;
- •15.Plantar Neuropathic DFU is located on an active Charcot foot;
- •16.Have hind foot ulcer or have a foot deformity/condition preventing the use of offload footwear;
- •17.Had a leg revascularization surgery within the last 6 months or be a candidate for revascularization surgery during the course of the study;
- •18.Glucocorticosteroid treatment (Prednisone >10 mg/day or its equivalent);
- •19.Ulcer decreased in size ≥ 30% during the screening period in the 2 weeks from size measurement after debridement to size at randomization;
- •20. Inability to stop alternative wound healing treatment (e.g. Becaplermin or other topical products) following debridement;
研究者
相似试验
进行中（未招募）
1 期
Clinical study to assess the efficacy and safety of gene therapy for the treatment of childhood cerebral adrenoleukodystrophyChildhood Cerebral Adrenoleukodystrophy (CCALD)MedDRA version: 18.0Level: PTClassification code 10051260Term: AdrenoleukodystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-001953-10-FRbluebird bio, Inc.15
进行中（未招募）
1 期
Clinical study to assess the efficacy and safety of gene therapy for the treatment of cerebral adrenoleukodystrophyCerebral Adrenoleukodystrophy (CALD)MedDRA version: 20.0Level: PTClassification code 10051260Term: AdrenoleukodystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-001953-10-DEbluebird bio, Inc.32
招募中
4 期
to compare the effect of fentanyl in heamodymanic changes during laryngoscopy and intubation(general anaesthesia) in normotensive vs hypertensive patientCTRI/2017/07/009103Department of Anaesthesiology Sir T Hospital Bhavnagar100
已完成
3 期
A phase III study of the safety and efficacy of povidone-iodine nasal spray (Nasodine”) in the treatment of subjects with the common cold in the natural setting.Common ColdInfection - Other infectious diseasesACTRN12619000764134Firebrick Pharma Pty Ltd256
进行中（未招募）
不适用
Phase III clinical trial comparing treatments of hormone-refractory prostate cancer (HRPC) with Docetaxel: continuous treatment vs. intermittent repetition of treatment after progression. - PRINCEEUCTR2005-001602-76-DECharité - Universitätsmedizin Berlin